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The Human Toxome Project is part of a long-term vision to modernize toxicity testing
for the 21st century. In the initial phase of the project, a consortium of six academic,
commercial, and government organizations has partnered to map pathways of toxicity,
using endocrine disruption as a model hazard. Experimental data is generated at
multiple sites, and analyzed using a range of computational tools. While effectively
gathering, managing, and analyzing the data for high-content experiments is a challenge
in its own right, doing so for a growing number of -omics technologies, with larger
data sets, across multiple institutions complicates the process. Interestingly, one of the
most difficult, ongoing challenges has been the computational collaboration between
the geographically separate institutions. Existing solutions cannot handle the growing
heterogeneous data, provide a computational environment for consistent analysis,
accommodate different workflows, and adapt to the constantly evolving methods and
goals of a research project. To meet the needs of the project, we have created and
managed The Human Toxome Collaboratorium, a shared computational environment
hosted on third-party cloud services. The Collaboratorium provides a familiar virtual
desktop, with a mix of commercial, open-source, and custom-built applications. It
shares some of the challenges of traditional information technology, but with unique and
unexpected constraints that emerge from the cloud. Here we describe the problems we
faced, the current architecture of the solution, an example of its use, the major lessons
we learned, and the future potential of the concept. In particular, the Collaboratorium
represents a novel distribution method that could increase the reproducibility and
reusability of results from similar large, multi-omic studies.
Keywords: computational toxicology, systems toxicology, cloud computing, big data, virtual machines,
virtualization
INTRODUCTION
The Human Toxome Project is part of an ongoing effort to modernize toxicity testing with new
technologies and a better understanding of toxicological mechanisms (National Research Council,
2007; Stephens et al., 2013). In particular, the project aims to map pathways of toxicity (PoT)
(Hartung and McBride, 2011; Kleensang et al., 2014), the molecular network perturbations that
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lead to an adverse outcome as opposed to normal homeostatic
change. A primary goal is to avoid prior bias, and instead
deduce PoTs using abundant, readily produced multi-omic
data and modern computational tools. In order to test the
concept and develop the techniques (Perkel, 2012; Baker, 2013;
Bouhifd et al., 2014), endocrine disruption in the human breast
adenocarcinoma cell line MCF-7 (Soule et al., 1973) was chosen
as a model system, and the experimental and computational
work was spread across a consortium of six institutions that
span the spectrum of academic, government, and commercial
interests: Agilent Technologies, Brown University, Georgetown
University, Johns Hopkins University (JHU) and its Center for
Alternatives to Animal Testing (CAAT), the Hamner Institutes
for Health Sciences, and the United States Environmental
Protection Agency (EPA) (Hartung et al., 2012, 2013; Bouhifd
et al., 2015).
Such a consortium is not unusual: scientific networks are
expanding, and funding agencies are emphasizing collaborations
(Adams, 2012, 2013). Likewise, -omics technologies continue
to improve, proliferate, and produce more high-quality data at
a faster rate (Marx, 2013; Khoury and Ioannidis, 2014). The
intersection of these two trends presents immediate challenges,
not just for toxicology, but for other fields as well. Here,
we enumerate the collaborative computational challenges we
encountered ourselves on the Human Toxome Project, and
describe how existing solutions are inadequate. We present our
own solution, The Human Toxome Collaboratorium, a shared
computational environment hosted on third-party cloud services.
We show how the Collaboratorium has facilitated computational
collaboration, and more importantly, served to further the
scientific goals of the project. Finally, we discuss the trade-offs
of collaboration in the cloud, some remaining challenges, and
potential future work.
COLLABORATIVE COMPUTATIONAL
CHALLENGES
Within the consortium, data are generated by different
laboratories at multiple sites using various technologies.
A simplified view of the overall workflow is depicted in Figure 1,
and the labs that perform each step are listed in Table 1.
Experimental data are generated via four technologies: genomic
data from array-based comparative genomic hybridization
(aCGH) microarrays, transcriptomic data from quantitative
reverse transcriptase-polymerase chain reaction (qRT-PCR),
gene expression (GX) microarrays, and metabolomic data from
liquid chromatography-mass spectrometry (LC-MS). Additional
experimental data have been incorporated from collaborations
and public repositories, including transcriptomic data from RNA
sequencing (RNA-seq) and proteomic data from LC-MS. The
experimental data are analyzed using a variety of computational
tools, which themselves can produce more data for analysis. The
entire workflow is complicated by the fact that different steps
are performed in different labs—as shown in Table 1—that may
be geographically distant, requiring coordination of effort. In
FIGURE 1 | Workflow within the Human Toxome Consortium. Experimental data are generated via four technologies: qRT-PCR, GX microarrays, aCGH
microarrays, and LC-MS (for metabolomics). Outside data from RNA-seq and LC-MS (for proteomics) have also been imported from public repositories or
collaborations. Data are analyzed via a variety of tools, often producing new data to be analyzed. In many cases, the individual steps may be performed at more than
one site, as shown in Table 1, adding to the complexity.
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TABLE 1 | Overlapping responsibilities within the Human Toxome
Consortium.
Results Brown JHU Georgetown CAAT Hamner Agilent
Cell culture × ×
RNA extract × × ×
DNA extract ×
Metabolite extract × ×
qRT-PCR × × ×
GX microarray ×
CGH microarray ×
LC-MS ×
Identified genes × × ×
Identified aberrations × ×
Identified metabolites × ×
Transcriptomic analysis × × × ×
Genomic analysis × ×
Metabolomic analysis × × ×
Proteomic analysis × × ×
Integrated analysis × × ×
For the workflows depicted in Figure 1, each step may be handled by a different
lab in the consortium, and the results transferred to another lab for further work.
To complicate matters, a given action may be performed by more than one lab,
depending on context. This table lists each step, as shown in Figure 1, and
indicates which lab or labs are responsible.
fact, a single step may be performed in different labs depending
on the context. This non-trivial experimental and analytical
pipeline is likely typical of many multi-omic efforts today, more
so for larger multi-omic research consortia. Within this complex
multi-omic, multi-site environment, we quickly encountered
many problems, particularly when it came to disseminating and
analyzing data. We eventually grouped these problems into four
major challenges: sharing data, duplicating the computational
environment, accommodating personal workflows, and adapting
to change.
Challenges Defined
Sharing data refers to the challenge of moving raw data, or even
processed results, from one site to another. Data sets are growing
ever larger in the chemical and biological sciences (Marx, 2013;
Khoury and Ioannidis, 2014), and depending on the bandwidth,
a modest 25 GB next-generation sequencing (NGS) data set can
take more than 24 h to transfer—an actual example already
encountered on the project. When multiple members want to
share the same large file, the pain is multiplied. In short, email
is no longer an option. In fact, all of the data should be made
available to all users, and backed up in case of loss.
Duplicating the computational environment refers to the
common problem of re-analyzing data at different sites or,
simply put, viewing results sent by a colleague. As a trivial
example, many people have attempted, and failed, to open
a “.doc” file without the appropriate version of Microsoft
WordTM. The problem is exacerbated in an environment with
multiple technologies and multiple, sometimes undocumented,
analytical pipelines. Every member of the consortium should
be able to open, view, and analyze any file they might
receive from another member. Moreover, members should
not have to consider hardware requirements or grapple
with software installation, configuration, licensing, and
updating.
Accommodating personal workflows refers to the fact that
members of the consortium—and collaborators in general—have
their own distinct analytical workflows and software preferences,
whether in operating systems, programming languages, libraries,
frameworks, applications, folder structure, or file naming
conventions. Furthermore, users have different technical abilities,
so the system should be easy to use and well documented, but
flexible enough to be overridden by those with particular skills.
Adapting to change is a common challenge in science: results
can be unexpected and the questions themselves can change.
As opposed to the rigid workflows one might encounter in an
industrial setting, workflows in research can be more fluid. For
example, on the Human Toxome Project, two-color microarrays
were replaced by one-color microarrays midway through the
project, requiring a change in workflow, including new reagents
and protocols, as well as a reorganization of sample names and
controls for each experiment. The computational tools should
handle such changes in personnel, protocols, experimental
design, technologies, and workflows.
Existing Solutions
In general, there are three common types of tools that enable
collaborative computation, either within an individual lab or
across a larger consortium: network-connected lab workstations,
shared remote servers, or web-based applications. The first
solution, connected lab workstations, is arguably the most
common, and many labs have already opted for it, whether
in the form of desktop computers in or near the lab, or
laptops carried by lab members. The solution is extremely
flexible, as each collaborator can customize their computational
environment to accommodate their own unique workflow. For
example, one person may use Bioconductor (Gentleman et al.,
2004) and R in a terminal on Linux in order to analyze
microarray data; whereas a colleague may run a similar analysis
using a commercial application with a graphical user interface
(GUI), running on Microsoft WindowsTM. The workstations are
usually connected via a network, although file sharing tends
to be ad hoc, most often via email or, occasionally, a shared
network file system. As file sizes grow, this ad hoc file sharing
becomes more cumbersome and difficult to manage, as each
person sends large files to the others, sometimes the same
large file, sometimes a slightly different version. The problem
is exacerbated by distance, usually due to lower bandwidth
over the Internet and the security restrictions in place at the
virtual border of each institution. A more subtle problem is
the need to install, configure, update, and license the required
software applications on all of the workstations. Often, this
is handled in an ad hoc fashion by the users themselves,
which hides the cost but does not eliminate it. Furthermore,
such ad hoc application management can impede collaboration
when a file cannot be viewed by a recipient because the
necessary application is not in place. Finally, the workstations
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are generally limited in computational power and take time to
upgrade.
The second common solution for computational collaboration
is a shared remote server, commonly accessed via network
protocols and associated applications such as Secure Shell
(SSH), Virtual Network Computing (VNC) (Richardson et al.,
1998), or Remote Desktop Protocol (RDP). Data and software
are more easily managed and shared, as the most recent
versions of interest are always available on the central server.
Furthermore, the central server is usually more powerful,
avoiding the limitations of personal workstations. However,
personal flexibility is often sacrificed in favor of centralized
management. Also, a single central system tends to be even more
difficult to change, or upgrade, than a personal workstation if
the research requirements shift. Furthermore, accessing a shared
remote server can be complicated by security restrictions at the
virtual borders of labs, buildings, or institutions. It should also
be noted that one of the most common methods of access,
SSH, is typically performed in a terminal, or at the so-called
command line, rendering the solution impractical for non-
experts.
The third solution, and possibly the most common modern
approach, is a web application, or web app. Several such
applications exist, including Galaxy (Goecks et al., 2010),
GenomeSpace1, the UCSC Genome Browser (Kent et al., 2002),
DNAnexus2, Seven Bridges3, and Illumina BaseSpace4. Some
are paid commercial applications; others are free and open-
source. Some provide a broad range of tools; others have a
narrow focus on a particular technology or workflow. Similar
to a shared server, web applications simplify the sharing of
data and software by centralizing the resources—indeed, the
web application itself is the software—with the added benefit
that web traffic is often allowed to flow freely through security
checkpoints at the virtual borders of many institutions, thus
simplifying remote access. Additionally, hardware concerns
are often eliminated, as disk drives, RAM, and CPUs are
managed behind-the-scenes. However, personal flexibility is
almost completely eliminated. The platforms generally do
not support legacy applications that are likely more familiar.
The web application is, in fact, a new application the user
must learn to do work. Also, web applications are often
purpose-built, and may not adapt well to a shift in research
focus.
Clearly, each of the existing solutions makes trade-offs, such as
sacrificing personal flexibility for easier centralized management
of the environment, that fail one or more of the collaborative
challenges described in the previous section. However, the
ongoing development and popularity of hardware virtualization
has given rise to so-called cloud services, such as Amazon
Web Services (AWS), Google Cloud Platform, and Microsoft
Azure, as well as more traditional offerings from Rackspace,
Linode, and Digital Ocean. These third-party services provide a
1GenomeSpace, http://www.genomespace.org/
2DNAnexus, http://www.dnanexus.com/
3Seven Bridges, http://www.sbgenomics.com/
4Illumina Basespace, http://basespace.illumina.com/
foundation upon which we developed an alternate solution, with
limited trade-offs, that is capable of meeting all four collaborative
challenges.
THE COLLABORATORIUM
The Human Toxome Collaboratorium is a set of virtual machines
(VMs) hosted on Amazon’s cloud service, AWS. In simple terms,
it is a virtual computer lab, albeit one with powerful new abilities.
New machines can be created, existing machines reconfigured,
and old ones discarded, in hours or sometimes minutes, all
via a remote interface. As such, the Collaboratorium can adapt
to changing research requirements. The primary interface for
users is the familiar Microsoft WindowsTM desktop, accessed
remotely via the Remote Desktop Protocol (RDP) from any
Windows, OS X, or Linux machine. Each new VM is created
based on a standard machine image, or template, that contains
a full complement of relevant software applications already
installed, licensed, and configured. Thus, each user begins with
an identical environment, making it easier to replicate analyses
and view colleagues’ results. On the other hand, users are
given full administrative privileges, allowing them to customize
their environment for their own preferred workflow. Finally,
important data is centralized on a single shared file system that
can be accessed from each VM in the Collaboratorium. The file
system is hosted on a Samba server using the common Server
Message Block (SMB) protocol over Amazon’s fast internal
network. The underlying Linux Logical Volume Manager (LVM)
provides the ability to dynamically expand the storage as needed.
All of the data is backed up daily to Amazon’s Simple Storage
Service (S3), a highly reliable object store. Once the data is
in the Collaboratorium, it can be seen and used by every
member of the Human Toxome Consortium easily. At present,
the Collaboratorium serves over 40 users, using approximately
10 VMs and 5 terabytes of disk space. The base image for a
new machine includes nearly 30 applications, which are listed
in Table 2, including a mix of commercial and open-source
software, along with software internally developed by members
of the consortium.
Overall, the Collaboratorium handles the collaborative
challenges better than the solutions previously described. The
data is centralized, so although the initial upload is relatively long,
subsequent processing is easier and data sharing is dramatically
faster. The VMs are centralized and shared, so everyone works
in the same computational environment. A remote login is
required, but as a result, application installation, configuration,
and licensing are simplified, and the appropriate application
for a given data set is always available. Personal workflows
are accommodated by installing requested software, or giving
users administrative access to do so themselves, while still being
monitored and managed. For unique workflows, new VMs
can be created and just as easily discarded. Indeed, the virtual
resources in the cloud allow for excellent adaptation over the
life of the project, especially relative to the fixed resources of the
typical computer lab: in the Collaboratorium, we have virtually
built machines with 16 CPUs and over 100 GB RAM to handle
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NGS sequencing, and then quickly disposed of them after the job
was done, minimizing the cost and maximizing the benefit. The
Collaboratorium has its own trade-offs, but they were carefully
considered and chosen to best handle the collaborative challenges
we faced.
Case Study: Analysis of Transcriptional
Events Induced by Estradiol
The goal of the Human Toxome Project is to elucidate PoTs using
multi–omics technologies and advanced bioinformatics. To this
end, the consortium has generated extensive gene, protein,
and metabolite expression datasets. To analyze the datasets,
the consortium has developed bioinformatics methods, geared
TABLE 2 | List of Collaboratorium software.
Application Technology Development
Agilent Pathway Architect
13.1.1
Integrated Biology Commercial
Agilent OpenLAB ELN 4.2.1.0 Integrated Biology Commercial
Hamner IDEA 1.0 Integrated Biology Internal
Agilent Feature Extraction
11.5.1.1
Microarray Commercial
Agilent QC Chart Tools 3.5.1.2 Microarray Commercial
Agilent CytoGenomics 2.9.2.4 Microarray Commercial
Agilent Genomic Workbench
7.0.4.0
Microarray Commercial
Agilent GeneSpring GX 13.1.1 Microarray Commercial
Agilent Mass Profiler
Professional 13.1.1
MS Commercial
Agilent MassHunter Qualitative
Analysis B.06.00 SP1
MS Commercial
Agilent MassHunter
Quantitative Analysis B.06.00
SP1
MS Commercial
Agilent PCDL Manager B.04.00
SP1
MS Commercial
Agilent Pathways to PCDL
B.05.00
MS Commercial
Agilent Molecular Structure
Correlator B.05.00
MS Commercial
Agilent MassHunter Profinder
B.06.00 SP1
MS Commercial
Strand NGS 2.1 NGS Commercial
Python 2.7.7 Platform Open Source
R 3.1.1 Platform Open Source
Oracle Java 7.0.650 Platform Open Source
Adobe Reader XI 11.0.09 Utility Commercial
Google Chrome 37 Utility Open Source
Libre Office 4.3.1.2 Utility Open Source
WinSCP 5.5.3 Utility Open Source
7-Zip File Manager 9.20 Utility Open Source
Notepad++ 6.6.9 Utility Open Source
PuTTY 0.63 Utility Open Source
At the time of writing, the Collaboratorium included almost 30 software packages
requested by members of the consortium. The list includes a mix of commercial,
open source, and internally developed applications used to analyze various –omics
technologies, along with general-purpose utilities and development platforms.
toward the requirements of identification and characterization
of PoTs, that incorporate multiple open source and commercial
software tools (see Table 2). Key examples of such methods
are weighted correlation networks that cluster genes by network
topology (Maertens et al., 2015), a sensitive method for gene
enrichment analysis called Information-dependent Enrichment
Analysis (IDEA) (Pendse et al., 2016), a robust method
for elucidating biological response by clustering based on
the responses of pathways rather than genes, as well as
numerous enhancements to Agilent commercial software that
were developed in response to the needs of the consortium,
including metadata and correlation frameworks, support for
KEGG pathways, and improved pathway visualizations. As
described above, the Human Toxome Collaboratorium has
been extensively used for all steps of data collection, sharing,
processing, and analysis.
A critical aspect of the Human Toxome Project is establishing
reproducibility of the results across different technologies,
experiments, and sites, and then comparing them to previously
published results. Integrating such a large, distributed,
heterogeneous set of data is a bioinformatics challenge that
is particularly well suited to the Collaboratorium approach.
Here we present an illustrative example of integrating gene
expression data from two technologies—microarrays and
RNA-seq—generated by multiple labs, in order to generate a
multidimensional dataset that yields a robust list of candidate
genes with reproducible transcriptional changes across several
independent studies in response to treatment by estrogen
agonists. MCF-7 cell cultures were treated at two independent
laboratories (Johns Hopkins and Brown Universities) with
the estrogen receptor ligands estradiol and propyl pyrazole
triol (PPT), at varying time and concentration points, and
profiled on Agilent gene expression microarrays as described
in Supplementary Material. Wet lab procedures and quality
controls followed the manufacturer’s recommendations. The
data was deposited in the Gene Expression Omnibus (GEO)
(Edgar et al., 2002; Barrett et al., 2013), under GSE77244.
Additionally, previously published microarray and RNA-seq
profiling datasets were drawn from GEO, including GSE36586
(Dahlman-Wright et al., 2012), GSE8597 (Bourdeau et al., 2008),
GSE24592 (Madak-Erdogan et al., 2011), GSE51403 (Liu et al.,
2014), GSE3529 (Rae et al., 2005), GSE4006 (Chang et al., 2006),
and GSE26459 (Gonzalez-Malerva et al., 2011). The data were
analyzed in the Human Toxome Collaboratorium environment
using Agilent GeneSpring GX for microarray analysis and Strand
NGS for RNA-seq analysis as well as to align raw sequencing
reads to the human genome.
A major challenge for identifying biomarkers of
environmental effects is the perceived lack of reproducibility
across studies performed by different authors. As part of the
Human Toxome Project we performed a joined analysis of
publicly available datasets of commonly studied breast cancer cell
lines exposed to estrogen and its agonists, combined with newly
generated transcript profiling data described here. Differential
expression analyses comparing estrogen- and agonist-treated
MCF-7 cells to their respective controls were performed taking
into consideration the unique experimental designs described
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in publications or data repository entries. As a result, we found
a small set of genes that exhibited reproducible expression
changes induced by treatment with estradiol (see Table 3). In
addition to establishing that many of the transcriptional effects
of estradiol treatment of MCF-7 cells showed a common set of
target genes, comparing gene expression profiling experiments
from microarray and RNA-seq datasets allowed us to create
detailed visualizations of similarities and differences, showing a
large overlap between the responders, as shown in Figure 2.
The ability to integrate data from several sources in a single
location, and perform direct data analysis of the large dataset
in a computationally unconstrained, collaborative analytical
environment, greatly increased our ability to interpret the data.
The Human Toxome Collaboratorium enabled different groups
involved in data analysis to review each other’s work in progress,
exploring new ideas in real time based on input from all members
of the distributed consortium. These capabilities led to exploring
novel data analyses that would not have been possible in a more
traditional computational environment.
New Challenges
Although cloud-based VMs can simplify the technical
administrative responsibilities, it should be made clear that
the need to actively monitor and manage the machines does not
disappear when working in the cloud. The Collaboratorium
is still a set of machines, albeit virtual, with traditional
TABLE 3 | Common estrogen responders.
Gene Symbol Regulation FC (abs) Description
Toxome GSE36586 GSE8597 GSE24592 GSE51403
ATP6V0A4 Down 1.54 3.38 1.22 19.15 3.72 ATPase, H+ transporting, lysosomal V0 subunit a4
ATP8A1 Down 1.43 3.02 1.79 22.1 2.4 ATPase, aminophospholipid transporter (APLT),
class I, type 8A, member 1
CDC25A Up 1.97 2.03 2.93 2.67 2.73 Cell division cycle 25A
CSTA Down 1.89 3.95 2.5 3.26 3.14 Cystatin A (stefin A)
CTNNAL1 Up 1.38 1.71 1.72 1.6 2.16 Catenin (cadherin-associated protein), alpha-like 1
CTNND2 Down 1.42 1.75 1.79 4.88 1.73 Catenin (cadherin-associated protein), delta 2
CTSD Up 1.37 3.15 1.58 1.73 3.07 Cathepsin D
CXCL12 Up 6.69 6.56 3.34 17.11 11.38 Chemokine (C-X-C motif) ligand 12
DSCC1 Up 1.89 2.22 4.07 2.49 2.89 DNA replication and sister chromatid cohesion 1
EGR3 Up 24.42 16.62 2.6 8.71 8.73 Early growth response 3
ELOVL2 Up 5.98 4.28 1.35 6.25 3.16 ELOVL fatty acid elongase 2
GREB1 Up 6.61 11.77 3.12 200.34 19.21 Growth regulation by estrogen in breast cancer 1
IGFBP3 Down 8.83 2.53 2.77 6.16 3.24 Insulin-like growth factor binding protein 3
IGSF1 Up 2.2 16.71 2.33 1.02 22.26 Immunoglobulin superfamily, member 1
MYB Up 4.98 3.4 2.35 2.19 3.61 v-myb avian myeloblastosis viral oncogene
homolog
OLFM1 Up 4.01 3.45 1.61 1.37 2.76 Olfactomedin 1
PGR Up 32.49 9.23 4.93 25.68 21.97 Progesterone receptor
PMP22 Down 1.88 2.58 1.81 2.89 2.69 Peripheral myelin protein 22
PPIF Up 2.75 1.74 2.28 9.95 1.55 Peptidylprolyl isomerase F
PRSS23 Up 3.43 5.86 1.57 14.76 5.53 Protease, serine, 23
RAB31 Up 9.07 2.84 2.84 7.79 3.18 RAB31, member RAS oncogene family
SERPINA3 Up 7.11 4.4 1.89 1.88 1.79 Serpin peptidase inhibitor, clade A (alpha-1
antiproteinase, antitrypsin), member 3
SGK1 Up 2.95 3.39 1.96 7.63 2.86 Serum/glucocorticoid regulated kinase 1
SLC35C1 Down 2.41 1.64 1.72 1.19 1.36 Solute carrier family 35 (GDP-fucose transporter),
member C1
SLC7A5 Up 2.32 3.12 1.68 4.59 2.98 Solute carrier family 7 (amino acid transporter light
chain, L system), member 5
TBC1D2 Down 1.51 1.99 1.29 3 2 TBC1 domain family, member 2
TMEM164 Up 3.83 3.43 2.07 1.59 2.29 Transmembrane protein 164
UPK1A Down 8.28 4.28 3.17 5.68 4.96 Uroplakin 1A
XBP1 Up 4.2 1.79 2.35 1.41 1.98 X-box binding protein 1
In addition to gene expression microarray data generated by the consortium (under the column labeled Toxome), gene expression microarray datasets were imported into
GeneSpring GX and RNA-seq data was aligned and quantified in Strand NGS. After normalization (quantile from microarray data and read-based for NGS), fold changes
from a list of estrogen responsive genes were exported from each experiment. The 29 genes displayed in this table changed in the same direction in response to estradiol
treatment in all five experiments, despite differences in doses and time points profiled. For details on previously published experiments see entries in Gene Expression
Omnibus and their respective references: GSE36586 (Dahlman-Wright et al., 2012), GSE8597 (Bourdeau et al., 2008), GSE24592 (Madak-Erdogan et al., 2011), and
GSE51403 (Liu et al., 2014). FC (abs) is defined as 2∧abs[log2(treated/control)].
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FIGURE 2 | Collaboratorium case study. The Collaboratorium provides a central location to gather data from multiple sources, along with readily available
software to analyze the data. This figure shows GeneSpring GX being used in the Collaboratorium to compare consortium-acquired gene expression microarray data
to publicly available RNA-seq data, in which a significant overlap in estradiol responsive genes was found. Two multi-omic analysis (MOA) tools in the software were
used for comparison: pathway analysis (left window) and cross-technology entity-entity correlation (right window).
information technology (IT) concerns. Security must be
addressed, including the management of user credentials, or
usernames and passwords, although security can be simplified in
the cloud if access is limited through a single Internet gateway.
Software must still be installed, configured, licensed, and updated
as necessary, although the job is simplified with machine images,
or snapshots, as the work must only be done once.
Some IT challenges subtly change in the cloud. For example,
in traditional IT capacity planning and provisioning, machines
and hard drives require a relatively large initial expenditure,
and usually require significant lead time due to technical or
budgetary reasons, which encourages over-provisioning in the
short term. On the other hand, the virtual cloud hardware
is generally leased by the hour, or some other unit of time,
and can be reconfigured or expanded quickly. As such, the
cloud encourages exact provisioning in the short term, and
re-provisioning as necessary. We learned this lesson during
the evolution of the Collaboratorium—we paid for VMs
that sometimes sat idle and virtual disks that were partially
empty. In an effort to minimize the cost, we reorganized
the shared storage to consolidate large files and eliminate
empty space. We implemented monitors that automatically
shut down idle machines after a period of inactivity. In short,
IT issues do not disappear in the cloud, and may in fact
mutate.
DISCUSSION
In toxicology—and in other scientific fields as well—handling
bigger data sets is a growing challenge, but it is just one
part of the larger challenge of collaboration. Consortia like
the Human Toxome Project already face the problem of
sharing data, establishing consistent environments to analyze
and view the data, doing so with a certain amount of personal
flexibility, and still allowing for research directions to change.
Thankfully, hardware virtualization provided by many third-
party cloud services enables projects such as the Human Toxome
Collaboratorium to meet these needs.
Since its inception, the Collaboratorium has evolved, and
continues to evolve. In the future, we plan to improve the
mechanisms used to import and export data to and from the
Collaboratorium and further reduce storage costs by avoiding
the duplication of large, unchanging files or using special
storage options, such as ephemeral storage for temporary files
or nearline storage for archives. We plan to further reduce
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the administrative overhead by improving and simplifying the
methods used for account management, license management,
and software upgrades. We also plan to demonstrate the concept
on other cloud, or virtualization, platforms. The goal is to create
and improve a portable environment that requires minimal
overhead.
Indeed, our experience with the Collaboratorium suggests a
tantalizing distribution mechanism for scientific results. Today,
published results might include a link to the source data
held in a public repository. However, the onus is on the
reader to download the data, carefully attempt to reconstruct
the appropriate computational environment, parse the data,
repeat the analysis, and match the published results, all before
any new analysis can take place. In the future, a publication
could instead include a link, not to the data files, but to a
live computational environment, where both the data and the
necessary software are ready to be used. Such a controlled
computational environment would likely increase the success
rate of examining and reproducing published analyses, as well
as encourage the use of the resulting methods in future work.
To demonstrate the potential of the concept, a working copy of
the Collaboratorium environment described in the case study,
including the software, datasets, and results, is available upon
request.
Not only does the Collaboratorium facilitate existing
collaborations, it encourages new ones. One deterrent to new
collaborative efforts, especially public–private partnerships, is the
difficult question of who makes the initial capital investment.
Traditionally, computational infrastructure can comprise a
significant portion of the initial investment. Today, VMs require
no initial investment; they only incur recurring costs. By re-using
a proven architecture and existing machine images, the startup
costs can be further decreased. Concomitantly, the question
of physical ownership, especially when there are competing
interests, is moot, as the machines are virtual. Furthermore,
thanks to the virtual infrastructure, computational environments
like the Collaboratorium can start small and scale quickly as
needed. Effectively eliminating the up-front costs could spur
new partnerships, and entirely new lines of inquiry, especially
computationally intensive ones.
The Human Toxome Collaboratorium was created to solve
our own collaborative needs: securely sharing data and software
between multiple research labs in different organizations with
different IT infrastructures, while still accommodating personal
preferences and changing workflows. The solution is a shared
computational environment hosted on third-party cloud services
that provides a familiar virtual desktop and a ready mix of legacy
and custom-built software, both commercial and open-source.
The virtual infrastructure is modest, and a similar environment
should serve the needs of a typical consortium, making the
Collaboratorium a potential blueprint for future collaborative
efforts.
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